2|0|Public
50|$|<b>Tiamenidine</b> (BAN, USAN, INN, {{also known}} as thiamenidine, Hoe 440) is a {{imidazoline}} compound that shares many of the pharmacological properties of clonidine. It acts as a centrally-acting α1 and α2 adrenergic receptor antagonist (with IC50 4.85 μM and 0.0091 μM, respectively). In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output. It was marketed (as <b>tiamenidine</b> hydrochloride) by Sanofi-Aventis under the brand name Sundralen {{for the management of}} essential hypertension.|$|E
50|$|Reaction of {{thiourea}} 1 with {{methyl iodide}} gives the corresponding S-methyl analogue (2), followed by heating with ethylenediamine, completes {{the synthesis of}} <b>tiamenidine</b> (3).|$|E

